Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Bimatoprost is safe and improves eyelash growth in healthy kids but not in those with eyelash loss from chemotherapy or alopecia.

A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.

The new nasal gel for schizophrenia improved drug absorption and brain effects in rats.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

The treatment was ineffective in humans.

Bimekizumab effectively treated a man's chronic beard hair loss.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

Erlotinib can cause hair loss and texture changes.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Nirogacestat can cause severe skin issues like hidradenitis suppurativa.

Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Erlotinib can cause hair loss as a side effect.

Testosterone creams and gels can be effective but have serious risks and should be used only with medical supervision.

Topical latanoprost and bimatoprost eye solutions don't help eyelash growth in people with alopecia areata.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Vitexin Compound 1 may help reduce skin aging caused by UVA light.

CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

Bimatoprost is safe and effective for treating eyelash loss caused by chemotherapy.

Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.